Quest Diagnostics has introduced three new cancer test services, which will enable clinicians to predict the development of hereditary forms of cancer in individuals.
The services are part of the company’s Quest Vantage cancer test menu. They will offer physicians and patients with clinically actionable insight and associated support capabilities.
They provide results interpretation, access to genetic counseling and prior authorization for health plan reimbursement.
The tests incorporate a 34-gene panel that includes various genes not identified on existing cancer risk panels.
With the help of next-generation sequencing and a bioinformatics platform, the new test services help in the identification of genetic variants related with inherited risk of 15 cancers such as breast, colorectal, pancreatic and renal.
MYvantage 34-gene hereditary comprehensive cancer panel includes 34 high risk and moderate risk and emerging risk genes associated with a spectrum of hereditary cancers.
GIvantage hereditary colorectal cancer test is comprised of 13 genes associated with colon and gastric cancers.
Qvantage hereditary women’s health cancer test includes 14 genes related with breast, colon, uterine, and ovarian cancers.
The GIvantage and Qvantage panels have been designed for patients with a limited subset of cancers in their family history. They only include genes for which national guidelines provide medical management recommendations for pathogenic or likely pathogenic gene variants.
Quest Diagnostics oncology general manager Christopher Fikry said: “The Quest Vantage service combines the latest advances in laboratory diagnostic technology with unmatched convenience and simplicity.
“With this menu, we deliver on our commitment to provide clinically actionable results based on the latest evidence and guidelines.”